Efficacy and Safety of Low-Dose Interleukin 2 for Primary Sjögren Syndrome: A Randomized Clinical Trial.

JAMA Netw Open · 2022 · PMC9650609 · PMID 36355371

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

There were reductions of IgG, anti-SSA, anti-SSB, and RF titers in the LD-IL-2 group, but some changes did not reach statistical significance (eTable 5 in Supplement 2 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.